Longitudinal monitoring of mRNA levels of regulatory T cell biomarkers by using non-invasive strategies to predict outcome in renal transplantation.
Adult
Biomarkers
/ blood
CTLA-4 Antigen
/ genetics
Female
Forkhead Transcription Factors
/ genetics
Gene Expression
Graft Rejection
/ genetics
Humans
Kidney Transplantation
Longitudinal Studies
Male
Middle Aged
Postoperative Complications
/ genetics
Predictive Value of Tests
RNA, Messenger
/ blood
T-Lymphocytes, Regulatory
/ physiology
Treatment Outcome
CTLA-4
Cellular acute rejection
DSA development
FOXP3
Graft dysfunction
Kidney transplantation
RT-PCR
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
02 02 2022
02 02 2022
Historique:
received:
22
02
2021
accepted:
15
09
2021
entrez:
3
2
2022
pubmed:
4
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Acute T-cell mediated rejection (aTCMR) is still an issue in kidney transplantation, for it is associated with chronic rejection, graft loss, and overall worse outcomes. For these reasons, a standard non-invasive molecular tool to detect is desirable to offer a simpler monitoring of kidney transplant recipients (KTRs). The purpose of our study was to examine, in peripheral blood before and after transplantation, the expression patterns of regulatory T cell (Treg)-related genes: the forkhead box P3 (FOXP3) and the two CTLA-4 isoforms (full-length and soluble) to predict acute rejection onset, de novo donor-specific antibodies (DSA) development and renal dysfunction 1 year after transplantation. We profiled by using a relative quantification analysis (qRT-PCR) circulating mRNA levels of these biomarkers in peripheral blood of 89 KTRs within the first post-transplant year (at baseline and 15, 60 and 365 days, and when possible at the acute rejection) and compared also the results with 24 healthy controls. The three mRNA levels drastically reduced 15 days after transplantation and gradually recovered at 1 year in comparison with baseline, with very low levels at the time of aTCMR for FOXP3 (RQ = 0.445, IQR = 0.086-1.264, p = 0.040), maybe for the pro-apoptotic role of FOXP3 during inflammation. A multivariate Cox regression analysis evidenced a significant relation between aTCMR onset and thymoglobuline induction (HR = 6.749 p = 0.041), everolimus use (HR = 7.017, p = 0.007) and an increased risk from the solCTLA-4 expression at 15 days, mainly considering recipients treated with Mycophelolic acid (HR = 13.94 p = 0.038, 95%CI:1.157-167.87). Besides, solCTLA-4 also predisposed to graft dysfunction (eGFR< 60 mL/min/1.73m mRNA levels of Treg-associated genes, mainly for solCTLA-4, in peripheral blood could put forward as candidate non-invasive biomarkers of cellular and humoral alloreactivity in clinical transplantation and might help shape immunosuppression, tailor monitoring and achieve better long-term outcomes of kidney transplantation in the wake of "precision medicine".
Sections du résumé
BACKGROUND
Acute T-cell mediated rejection (aTCMR) is still an issue in kidney transplantation, for it is associated with chronic rejection, graft loss, and overall worse outcomes. For these reasons, a standard non-invasive molecular tool to detect is desirable to offer a simpler monitoring of kidney transplant recipients (KTRs). The purpose of our study was to examine, in peripheral blood before and after transplantation, the expression patterns of regulatory T cell (Treg)-related genes: the forkhead box P3 (FOXP3) and the two CTLA-4 isoforms (full-length and soluble) to predict acute rejection onset, de novo donor-specific antibodies (DSA) development and renal dysfunction 1 year after transplantation.
METHODS
We profiled by using a relative quantification analysis (qRT-PCR) circulating mRNA levels of these biomarkers in peripheral blood of 89 KTRs within the first post-transplant year (at baseline and 15, 60 and 365 days, and when possible at the acute rejection) and compared also the results with 24 healthy controls.
RESULTS
The three mRNA levels drastically reduced 15 days after transplantation and gradually recovered at 1 year in comparison with baseline, with very low levels at the time of aTCMR for FOXP3 (RQ = 0.445, IQR = 0.086-1.264, p = 0.040), maybe for the pro-apoptotic role of FOXP3 during inflammation. A multivariate Cox regression analysis evidenced a significant relation between aTCMR onset and thymoglobuline induction (HR = 6.749 p = 0.041), everolimus use (HR = 7.017, p = 0.007) and an increased risk from the solCTLA-4 expression at 15 days, mainly considering recipients treated with Mycophelolic acid (HR = 13.94 p = 0.038, 95%CI:1.157-167.87). Besides, solCTLA-4 also predisposed to graft dysfunction (eGFR< 60 mL/min/1.73m
CONCLUSIONS
mRNA levels of Treg-associated genes, mainly for solCTLA-4, in peripheral blood could put forward as candidate non-invasive biomarkers of cellular and humoral alloreactivity in clinical transplantation and might help shape immunosuppression, tailor monitoring and achieve better long-term outcomes of kidney transplantation in the wake of "precision medicine".
Identifiants
pubmed: 35109826
doi: 10.1186/s12882-021-02608-3
pii: 10.1186/s12882-021-02608-3
pmc: PMC8809010
doi:
Substances chimiques
Biomarkers
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
FOXP3 protein, human
0
Forkhead Transcription Factors
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
51Informations de copyright
© 2022. The Author(s).
Références
Eur J Immunol. 2013 May;43(5):1274-85
pubmed: 23400950
Transplant Direct. 2019 Feb 08;5(3):e426
pubmed: 30882031
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15448-53
pubmed: 17873064
Nephrol Dial Transplant. 2012 Jun;27(6):2576-82
pubmed: 22167587
Trends Immunol. 2011 Sep;32(9):428-33
pubmed: 21723783
Transpl Immunol. 2008 May;19(2):93-102
pubmed: 18503884
J Immunol. 2000 May 15;164(10):5015-8
pubmed: 10799854
PLoS One. 2012;7(9):e44654
pubmed: 23049754
Am J Transplant. 2019 Jan;19(1):89-97
pubmed: 29947147
Scand J Immunol. 2003 Jun;57(6):568-72
pubmed: 12791095
Nat Immunol. 2003 Dec;4(12):1206-12
pubmed: 14578884
Annu Rev Immunol. 2012;30:531-64
pubmed: 22224781
Front Immunol. 2012 Mar 21;3:51
pubmed: 22566933
Nat Rev Immunol. 2011 Nov 25;11(12):852-63
pubmed: 22116087
Rheumatology (Oxford). 2005 Aug;44(8):989-94
pubmed: 15870153
Immunology. 2011 Sep;134(1):17-32
pubmed: 21711350
J Am Soc Nephrol. 2014 Aug;25(8):1856-68
pubmed: 24652799
Nat Immunol. 2002 Nov;3(11):1097-101
pubmed: 12368911
Clin Exp Immunol. 2019 Jul;197(1):14-23
pubmed: 30076771
Transpl Int. 2007 Feb;20(2):118-27
pubmed: 17239019
Am J Transplant. 2019 Jan;19(1):5-8
pubmed: 30125470
Hum Immunol. 2018 May;79(5):343-355
pubmed: 29366869
Clin Exp Immunol. 2015 May;180(2):329-40
pubmed: 25557528
Am J Transplant. 2020 Jan;20(1):75-87
pubmed: 31250973
J Am Soc Nephrol. 2014 Jul;25(7):1586-97
pubmed: 24610929
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Curr Opin Organ Transplant. 2010 Feb;15(1):35-41
pubmed: 19935064
Hum Immunol. 2012 Mar;73(3):282-6
pubmed: 22245568
J Neuroimmunol. 2002 Sep;130(1-2):224-32
pubmed: 12225905
Am J Transplant. 2017 Jan;17(1):28-41
pubmed: 27862883
Am J Transplant. 2016 Apr;16(4):1045-6
pubmed: 26613671
Am J Transplant. 2017 Jun;17(6):1490-1501
pubmed: 27888555
Transplant Proc. 2013 Sep;45(7):2645-9
pubmed: 24034013
Hum Immunol. 2010 Oct;71(10):934-41
pubmed: 20650297
Trends Immunol. 2018 Oct;39(10):771-774
pubmed: 30195467
Inflamm Allergy Drug Targets. 2006 Dec;5(4):239-42
pubmed: 17168794
Kidney Int. 2008 Apr;73(7):877-84
pubmed: 18216781
N Engl J Med. 2005 Dec 1;353(22):2342-51
pubmed: 16319383
N Engl J Med. 2013 Jul 4;369(1):20-31
pubmed: 23822777
Nature. 2007 Feb 15;445(7129):766-70
pubmed: 17220876
Eur J Immunol. 1999 Nov;29(11):3596-602
pubmed: 10556814
J Am Soc Nephrol. 2018 Mar;29(3):1049-1062
pubmed: 29321143
Science. 2011 Apr 29;332(6029):600-3
pubmed: 21474713
J Exp Med. 2000 Jul 17;192(2):303-10
pubmed: 10899917
Clin Immunol. 2007 May;123(2):190-8
pubmed: 17321799
BMC Nephrol. 2015 Nov 03;16:182
pubmed: 26525294
Transplantation. 2011 Jan 27;91(2):191-8
pubmed: 21157405
BMC Nephrol. 2015 Aug 19;16:146
pubmed: 26286066
Blood Purif. 2016;42(4):307-313
pubmed: 27694753
Clin J Am Soc Nephrol. 2013 Aug;8(8):1396-405
pubmed: 23580782
Transplantation. 2014 Dec 15;98(11):1213-8
pubmed: 25083613